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Abstract
Background: It is widely recognized that inflammation promotes breast cancer invasion and metastasis. Given the
complex nature of the breast tumor inflammatory microenvironment, much remains to be understood of the
molecular mechanisms that govern these effects. We have previously shown that osteoprotegerin knockdown
in breast cancer cells resulted in reduced invasion and metastasis. Here we present novel insight into the role
of osteoprotegerin in inflammation-driven tumor progression in breast cancer by investigating the link between
osteoprotegerin, macrophages and the potent pro-inflammatory cytokine Interleukin-1beta.
Methods: We used human breast cancer cell lines to investigate the effects of Interleukin-1beta treatment on
osteoprotegerin secretion as measured by ELISA. We analyzed public datasets containing human breast cancer
genome-wide mRNA expression data to reveal a significant and positive correlation between osteoprotegerin
mRNA expression and the mRNA expression of Interleukin-1beta and of monocyte chemoattractant protein
CC-chemokine ligand 2. Osteoprotegerin, Interleukin-1beta and CC-chemokine ligand 2 mRNA levels were also
examined by qPCR on cDNA from normal and cancerous human breast tissue. We determined the effect of
Interleukin-1beta–producing macrophages on osteoprotegerin expression by co-culturing breast cancer cells
and differentiated THP-1 macrophages. Immunohistochemistry was performed on human breast tumor tissue
microarrays to assess macrophage infiltration and osteoprotegerin expression. To demonstrate that osteoprotegerin
mediated functional effects of Interleukin-1beta we performed cell invasion studies with control and OPG siRNA
knockdown on Interleukin-1beta-treated breast cancer cells.
Results: We report that Interleukin-1beta induces osteoprotegerin secretion, independent of breast cancer subtype
and basal osteoprotegerin levels. Co-culture of breast cancer cells with Interleukin-1beta-secreting macrophages
resulted in a similar increase in osteoprotegerin secretion in breast cancer cells as Interleukin-1beta treatment.
Macrophage infiltration correlates with osteoprotegerin secretion in human breast tumor tissue samples. We
show that osteoprotegerin secretion is regulated by Interleukin-1beta in a p38- and p42/44-dependent manner.
We also demonstrate that osteoprotegerin knockdown represses Interleukin-1beta expression, Interleukin-1beta-
mediated breast cancer cell invasion and MMP3 expression.
Conclusions: These data indicate a novel role for osteoprotegerin as a mediator of inflammation- promoted
breast cancer progression.
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Background
The association between inflammation and cancer devel-
opment has recently received wide recognition as a cancer
hallmark [1]. Persistent inflammation contributes to the
progression of cancer by promoting tumor survival, prolif-
eration, angiogenesis, metastasis, and immune evasion [2].
The processes involved in cancer-associated inflammation
entail complex interactions between the tumor cells and
the tumor microenvironment. The key mediators include
inflammatory cells and pro-inflammatory cytokines. In-
flammatory cells, in particular tumor-associated macro-
phages (TAMs), are present in most malignant tumors,
and high TAM density is correlated with poor prognosis
[2–4]. Amongst the cells in the tumor microenvironment
and tumor cells themselves, TAMs serve as a major source
of pro-inflammatory cytokines that influence tumor pro-
gression [3]. Abundant at tumor sites, IL-1 is one of the
most potent pro-inflammatory cytokines that can modu-
late the growth and invasive properties of tumor cells [3].
IL-1 exists in two agonistic forms, IL-1alpha and -beta
(IL1B). IL1B is active as a secreted form whereas IL-
1alpha is active as an intracellular protein. Elevated IL1B
levels in tumor and serum are associated with higher
tumor grade and increased invasion in breast and pancre-
atic cancer and in myelogenous leukemia, and are corre-
lated with poor patient outcome [5–10]. Ultimately, the
primary cause of mortality from cancer is due to metasta-
sis, the spreading of primary tumor cells to distant sites to
form secondary tumors. IL1B has been shown to play a
significant role on tumor invasiveness and metastasis pro-
gression [9, 11–13]. Studies in vivo showed reduced hep-
atic and lung metastasis of B16 melanoma cell xenografts
in IL1B knockout mice [11, 12]. In human breast carcin-
oma tissues, IL1B levels were found elevated in higher
grade tumors [14] and in invasive breast carcinoma versus
ductal carcinoma in situ (DCIS) and benign lesions [5].
IL1B has been shown to up-regulate Osteoprotegerin
(OPG) expression in the breast cancer cell lines MCF-7
and MDA-MB-231 [15]. OPG is a secreted member of
the tumor necrosis factor (TNF) receptor super-family,
prominently known for its role as a decoy receptor in
bone resorption in vivo, and for its inhibition of TNF-
related apoptosis-inducing ligand (TRAIL) mediated
apoptosis in vitro [16, 17]. There is increasing evidence
for a role of OPG in cancer, as OPG expression has been
found elevated in more aggressive solid tumors [18–21].
A number of studies support a tumor-promoting effect
of OPG in breast cancer [22]. OPG over-expression in
MCF-7 (estrogen receptor, ER+) breast cancer cells re-
sulted in increased tumor growth and osteolysis in
mouse xenografts [23]. Recently, we reported that
siRNA-mediated OPG knockdown in triple-negative
breast cancer cells reduced invasion and metastasis in a
chick embryo in vivo model [24]. Based on these
findings we hypothesized that IL1B modulates breast
cancer invasion and metastasis by OPG regulation.
Breast cancer metastasis poses significant treatment
challenges. Furthering our understanding of the molecu-
lar processes involved is essential for novel therapeutic
strategies for metastatic breast cancer. In this current
study, we investigate the IL1B-mediated upstream sig-
naling events involved in OPG expression, look into the
involvement of macrophages in OPG expression, and
examine the link between OPG and IL1B as a novel in-
flammatory pathway promoting breast cancer metastasis.
Methods
Reagents and cell culture
Recombinant human IL1B (200-01B) and IL-1R antag-
onist (IL1-RA, 200-01R) were purchased from Peprotech
(Rocky Hill, NJ). p38 MAPK (8690), phospho-p38
MAPK (Thr180/Tyr182; 4511), p42/44 MAPK (9107S),
phospho-p42/44 MAPK (Thr202/Tyr204; 9101) anti-
bodies were purchased from Cell Signaling Technology
(Beverly, MA). MAPK inhibitors SP600125, SB202190
and SB203580 were purchased from Sigma Aldrich (St
Louis, MO), U0126 and BAY869766 were purchased
from Santa Cruz Biotechnologies (Santa Cruz, CA).
The human breast cancer lines: MDA-MB-231, MDA-
MB-436, BT549, SKBR3, ZR75-1, HCC1954 were cul-
tured in Dulbecco’s Modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS; Atlanta
Biologicals, Lawrenceville, GA), 2 mM L-glutamine, and
50 μg/mL gentamicin (Life Technologies, Carlsbad, CA).
THP-1 monocyte cells were cultured in RPMI 1640 sup-
plemented with 10% FBS, 2 mM L-glutamine, 1 mM so-
dium pyruvate, 10 mM HEPES, and 1% antibiotic/
antimycotic solution (15240062, Life Technologies).
All cell lines were recently acquired from the ATCC
(Manassas, VA). Cell lines were incubated in a hu-
midified atmosphere of 5% CO2 at 37 °C.
Enzyme-linked immunosorbent assay
5 × 105 breast cancer cells were seeded in 2 mL of
medium in a 6 well plate and incubated for 48 h. Treat-
ment with IL1B or IL-1RA was administered for the last
24 h. OPG protein from cell culture supernatant was
measured using the OPG/TNFRSF11B DuoSet (R&D
Systems, Minneapolis, MN). IL1B protein from cell cul-
ture supernatant was measured using the Human IL1B
ABTS ELISA Development Kit (Peprotech).
Western blot
Protein extracts were obtained by cell lysis in M-PER
(Pierce Biotechnology, Rockford, IL) and Halt protease
inhibitor cocktail (Pierce Biotechnology). Proteins were
separated by SDS-PAGE and blotted onto nitrocellulose
membranes. Membranes were blocked with Blocking
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Buffer (LI-COR, Lincoln, NE) and incubated with specific
antibodies. Protein signals were visualized using the Odys-
sey infra-red imaging scanner and software (LI-COR).
Real-time polymerase chain reaction
Total RNA was extracted from breast cancer cells using
the RNeasy kit (Qiagen, Germantown, MD). cDNA was
prepared from RNA (200 ng) in a 20 μL reaction using
the iScript cDNA synthesis kit (Biorad, Hercules, CA).
qRT-PCR reactions were performed in 25 μL mixtures
containing 1 μL of cDNA, 2x iQ SYBR Green supermix
(Biorad), and forward and reverse primers. cDNA’s di-
luted 1:3 were used for the qRT-PCR reactions of the
18S rRNA housekeeping gene. See Additional file 1:
Table S1 for primer sequences. mRNA was normalized
to 18S rRNA. Relative expression was determined by the
ΔΔCT method [25].
siRNA transfection
Breast cancer cells were transfected with OPG Stealth
RNA siRNA (Stealth siRNAs for human OPG:
HSS107349 [#1], HSS181651 [#2] and HSS181652 [#3])
or Negative Control Medium GC siRNA using Lipofec-
tamine RNAiMax, according to the manufacturer’s in-
structions (all from Life Technologies).
Transwell co-culture assay
On Day 0, 1 ×106 THP-1 cells/well were seeded into a 6
well plate. On Day 1, the THP-1 cells were treated with
1 mM PMA to induce macrophage differentiation, and 5
× 105 breast cancer cells were seeded onto polycarbon-
ate inserts for 6-well plates (pore size 0.4 μm; Corning
Costar, Tewksbury, MA). On Day 2, 4 mL of fresh THP-
1 medium was placed onto the THP-1 cells prior to the
transfer of the transwell inserts containing the breast
cancer cells. The co-cultures were incubated for 8 h in a
humidified atmosphere of 5% CO2 at 37 °C.
Invasion assay
MDA-MB-436 cells were transfected with OPG or nega-
tive control siRNA as described above. Twenty-four
hours post-transfection, cells were treated with IL1B
(10 ng/mL) in medium containing 0.5% FBS for another
24 h. Following treatment, cells were seeded at 5 × 104
cells/well into a 96 well cell invasion chamber plate pre-
coated with 1x Collagen IV using the Cultrex 96 Well
Collagen IV Cell Invasion Assay (3458-096-K, Trevigen,
Gaithersburg, MD),. The invasion assay was incubated
for 24 h and analyzed according to the manufacturer’s
instructions.
Public dataset analysis
Human breast cancer genome-wide mRNA expression
datasets from patient sample series deposited for public
access in a MIAME-compliant format were obtained
through the Gene Expression Omnibus (GEO) database
at the NCBI website (http://www.ncbi.nlm.nih.gov/geo/),
except for the Chin-124 set (E-TABM-158) from EMBL/
EBI (http://www.ebi.ac.uk/arrayexpress), and two TCGA
sets from https://gdc-portal.nci.nih.gov/. Datasets
were analyzed using R2; a genomics analysis and
visualization platform developed in the Department of
Oncogenomics, Academic Medical Center, Amsterdam,
The Netherlands (http://r2.amc.nl/). Expression data
were uploaded into R2 and analyzed as described previ-
ously [26]. Briefly, gene transcript levels from Affymetrix
array studies were determined from data image files
using GeneChip operating software MAS5.0 and
GCOS1.0, from Affymetrix (Santa Clara, CA). Samples
were scaled by setting average intensity of the middle
96% of probe signals to a fixed value of 100 for every
sample in the dataset, allowing comparisons between
micro-arrays. The Illumina arrays for Servant-343 and
Jonsdottir-94, and the Agilent arrays for TCGA-528
and −1097 underwent custom processing and
normalization as described on their websites. All 29 public
datasets were scrutinized for OPG (TNFRSF11B gene)
mRNA expression and OPG-correlating genes. 13 datasets
with a sample size < 100 and/or the absence of OPG
mRNA expression or correlating genes were omitted from
further analysis: Black-107 (GSE36771), Clynes-121
(GSE42568), Concha-66 (GSE29431), Desmedt-55
(GSE16391), Jonsdottir-94 (GSE46563), Loi-77 (GSE9195),
Miller-116 (GSE5462), Minn-96 (GSE2603), Prat-156
(GSE50948), Quiles-61 (28844), Sotiriou-120 (GSE16446),
Sotiriou-198 (GSE7390), and Wessels-60 (GSE41656). The
TranscriptView tool (http://bioinfo.amc.uva.nl/human-
genetics/transcriptview/) was used to select probe-sets for
the Affymetrix and Illumina datasets. No sequence data
were available for the two TCGA datasets. Probes had to
show unique mapping in an anti-sense position within
(late) coding exons and/or the 3’ UTR of the gene. When
multiple correct probe-sets were available for a gene, the
probe-set with the highest average expression and the
highest amount of present calls for that dataset were used.
All probe-sets used meet these criteria. In no cases did
additional probe-sets show a conflicting result for that
dataset.
Gene expression analysis of human breast cancer and
normal tissues
qPCR was performed to characterize the OPG, IL1B and
CCL2 mRNA expression profiles using the TissueScan
Breast Tissue qPCR Array (OriGene, Technologies,
Rockville MD) containing cDNA from normal and
breast cancer tissue from different disease stages. See
Additional file 1: Table S1 for primer sequences. Data
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were presented as delta Ct values normalized against
β-actin.
Immunohistochemistry
Human breast cancer tissue microarray slides (Abcam,
Cambridge, MA) were separately immunostained for OPG
(Abcam) and CD68 (Dako North America, Inc. Carpinteria,
CA). Following deparaffinization in xylene and rehydration,
slides were subjected to antigen retrieval (10 mmol/L cit-
rate buffer; pH 6.0), followed by 3% hydrogen peroxide in-
cubation, and blocking in 1.5% goat serum. Slides were
then incubated with diluted primary antibody followed by
incubation with HiDef amplifier secondary antibody, and
detection with HiDef polymer (Cell Marque Laboratories,
Rocklin, CA) and DAB substrate (3,3-diaminobenzidine;
Cell Marque Laboratories). Counterstaining was performed
with hematoxylin. The tissue sections were scored semi-
quantitatively by a pathologist based on staining intensity.
Staining and analyses were performed by the University of
Hawaii Cancer Center-Pathology Shared Resource.
Statistical analysis
Results are presented as mean ± SD. Statistical analyses
were determined using a Student’s t-test, as indicated in
the text. Analyses were performed and graphs were plot-
ted in Prism V6 (GraphPad Software). Correlations be-
tween OPG and CCL2/IL1B mRNA expression (Fig. 4)
were calculated using R2. Briefly, a Pearson test was per-
formed on 2log-transformed expression values (with the
significance of a correlation determined by t = r/sqrt((1-
r^2)/(n-2)), where r is the correlation value and n is the
number of samples, and distribution measure is approxi-
mately as t with n-2° of freedom). Correlations were only
calculated for datasets when ≥ 10% of samples had a
present call for both genes. For all statistical analyses,
p < 0.05 was considered significant.
Results
IL1B induces OPG expression in different subtypes of
breast cancer cells
Basal levels of OPG and IL1B protein were examined
across cell lines representing multiple breast cancer sub-
types. Triple-negative breast cancer (TNBC) cells, the
most aggressive breast cancer subtype, lack ER and pro-
gesterone receptor (PR) expression, and do not show ex-
pression or amplification of the Her2/neu receptor. The
TNBC cell lines included in this study, MDA-MB-436,
MDA-MB-231 and BT549, were found to secrete higher
basal OPG levels than the non-TNBC cell lines T47D,
ZR75-1 (both ER+), HCC1954, or SKBR3 (both HER2+;
Fig. 1a). Elevated IL1B levels are associated with poor
prognosis in cancer, including breast cancer [27, 28]. A
study that examined human tissue extracts reported
higher IL1B levels in invasive breast carcinoma
compared to non-invasive breast tumors [5]. As seen in
Fig. 1b, the TNBC lines secreted higher basal IL1B levels
compared to the non-TNBC lines. Exogenous IL1B can
induce OPG expression in human breast cancer and
other cancer cell lines [15, 19, 29]. We therefore asked
whether breast cancer cells with higher basal OPG and
IL1B secretion levels show different responses to IL1B-
induced OPG expression. To test this, breast cancer cells
were treated with IL1B (10 ng/mL) for 24 h. Regardless
of the basal OPG/IL1B levels, exogenous IL1B signifi-
cantly induced both OPG mRNA (Fig. 1c) and OPG se-
cretion (Fig. 1d). Notably, cell lines with very low to
undetectable basal OPG protein levels, e.g. the non-
TNBC cell lines SKBR3, HCC1954 and ZR75-1, showed
the highest IL1B-mediated induction of OPG secretion
(SKBR3, 880.0 ± 48.7; HCC1954, 448.0 ± 88.2; ZR75-1,
1653.2 ± 927.7; data presented as mean ± S.D. pg/mL). In
these cells, IL1B could induce OPG levels comparable to
the basal levels of the TNBC MDA-MB-436 cells (805.9
± 185.6 pg/mL; Fig. 1d).
TNBC-type cell lines exhibited the highest basal OPG
and IL1B secretion levels. To evaluate whether basal
IL1B influences the basal OPG levels also in these cells,
we treated MDA-MB-436 cells with an IL-1B receptor
antagonist (IL-1RA, 50 ng/mL) for 48 h. We observed
that IL-1RA treatment significantly lowered the OPG
mRNA and secreted protein levels (Fig. 1e and f). This
finding, along with the observed correlated elevation of
OPG and IL1B in TNBCs (Fig. 1a and b), suggests an
IL1B autocrine loop for OPG production that may be
characteristic of breast tumor progression. Overall, our
data shows OPG can be induced across different breast
cancer subtypes independent of basal OPG and IL1B se-
cretion levels.
IL1B upregulates OPG expression by activation of the p38
and p42/44 MAPK signaling pathway
The metastatic potential of cancer cells, including breast
cancer cells, can be enhanced through mitogen-activated
protein kinase (MAPK) signaling [30–35]. To explore
the potential involvement of MAPK activation in IL1B-
mediated OPG secretion, we first assessed the effects of
IL1B treatment on phosphorylation of the p38, p42/44
and JNK MAPK pathway kinases by Western blot and
densitometry analysis as shown in Fig. 2. IL1B treatment
resulted in increased phosphorylation as compared to
untreated controls in all five breast cancer cell lines
tested for p38, and in four out of five cell lines tested for
p42/44. While IL1B treatment also showed a pattern of
increased JNK phosphorylation, the increase was only
significantly different from untreated cells in two out of
the five cell lines tested. We next tested the effects of
the p38 (SB203580 and SB202190), p42/44 (U0126 and
BAY869766) and JNK (SP600125) inhibitors in three
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breast cancer cells lines representative of the three sub-
types (BT549, ZR75-1 and SKBR3). Breast cancer cells
were simultaneously treated with MAPK inhibitors
(10 μM) and IL1B (10 ng/mL) for 24 h. We observed
that the p38 and p42/44 inhibitors repressed the IL1B-
mediated induction of OPG mRNA (Fig. 3a) and
secreted OPG protein (Fig. 3b) in all three breast cancer
cell lines tested. In contrast, treatment with JNK inhibi-
tor did not reduce OPG mRNA and OPG secreted pro-
tein levels. Given that the p38 and p42/44 signaling
pathways significantly repressed the IL1B-mediated OPG
secretion, we next explored the effects of dual inhibition.
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Fig. 1 IL1B induces OPG secretion in breast cancer cell lines regardless of subtype and basal OPG protein levels. a Basal OPG and b IL1B protein
levels were assessed by ELISA on supernatant collected from several different breast cancer cell lines, (n≥ 3). c Relative OPG mRNA measured by
qRT-PCR and d OPG secreted protein levels increase upon treatment with IL1B (10 ng/mL) in several different breast cancer cell lines, (n≥ 3). e
OPG RNA and f OPG secreted protein levels decrease upon treatment with PBS or IL-1B receptor antagonist IL-1RA (50 ng/mL) of MDA-MB-436
cells (n = 4). Data are represented by mean ± SD. Asterisks indicate statistical significance (p < 0.05)
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Breast cancer cells were treated with both p38
(SB202190) and p42/44 (U0126) MAPK inhibitors simul-
taneously with IL1B for 24 h. Dual inhibition resulted in
further repression of IL1B-mediated OPG secretion to
levels lower than the respective single inhibitor treatments
and comparable to basal levels (Fig. 3b). These results sug-
gest the p38 and p42/44 MAPK pathways play important
roles in the IL1B-mediated OPG up-regulation in breast
cancer cells.
High OPG mRNA expression correlates to high IL1B and
CCL2 mRNA expression in human breast cancer samples
The results above clearly show a role for IL1B in in-
creasing OPG secretion in breast cancer cell lines in
vitro (Fig. 1a-d). To ascertain that these experiments re-
flect the in vivo situation, in human breast tumors, we
performed data mining on publicly available human
breast cancer mRNA expression datasets derived from
patient samples. We were able to analyze 13 different
public datasets (for details see Methods). We found that
OPG mRNA expression significantly, positively corre-
lated with IL1B mRNA expression in 11 out of 13 data-
sets (Table 1), in agreement with what we observed for
OPG and IL1B secretion in the breast cancer cell lines
in vitro. Since the results were so consistent, over 11 of
13 datasets, which had very different tumor subtype and
grade compositions, contained patients from diverse
geographical regions, and were analyzed on four separate
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Fig. 2 IL1B induces p38, p42/44 and JNK phosphorylation in breast cancer cell lines. Western blot analysis showing a p38 b p42/44 and c
JNK phosphorylation increases after 30 min treatment with IL1B (10 ng/mL) in breast cancer cell lines. Densitometry analysis shown
below each respective blot represents fold change of phosphorylated protein normalized to the respective total protein, relative to the
control. Data are represented by mean ± SD. Asterisks indicate statistical significance (p < 0.05)
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array platforms, we propose that these results are very
robust. OPG mRNA expression was also found to cor-
relate with CC-chemokine ligand 2 (CCL2) in all 13
datasets (Table 1).
OPG, IL1B, and CCL2 mRNA in normal and breast
cancer human tissue samples were determined by qPCR
using a panel of commercially available cDNAs (see
Methods). Data was presented as delta Ct values normal-
ized against β-actin (Ct value for genes of interest minus
Ct value of β-actin). Higher expression levels are de-
noted by relative lower delta Ct values and lower levels
of expression are denoted by relative higher delta Ct
values. We observed statistically significant higher
mRNA expression levels (lower delta Ct values) for
CCL2 (Fig. 4a), IL1B (Fig. 4b) and OPG (Fig. 4c) in the
stage I breast cancer samples relative to normal samples.
The overall patterns observed in the qPCR analysis of
a small subset of human breast cancer tissue samples
are in agreement with the findings from the public data-
set analysis (Table 1) thereby supporting the positive
correlation of OPG-CCL2 and OPG-IL1B mRNA ex-
pression in breast cancer.
Macrophage co-culture-induced IL1B elevates OPG
expression in breast cancer cells
CCL2 is a potent chemokine involved in the recruitment
of monocytes to sites of tissue injury and infection. High
breast cancer CCL2 levels are associated with tumor asso-
ciated macrophage (TAM) infiltration [36]. The mecha-
nisms by which macrophages promote tumor progression
are not fully understood. Taking into account the correl-
ation between OPG and CCL2 mRNA expression, we next
examined whether macrophages can induce OPG secre-
tion in breast cancer cells. We hypothesized that macro-
phages could be a source of IL1B that would further
stimulate OPG secretion in breast cancer cells. We there-
fore performed co-culture experiments with macrophages
and breast cancer cells representative of different subtypes
(MDA-MB-436, SKBR3, and ZR75-1). THP-1 monocytes
were seeded and allowed to differentiate to macrophages
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Fig. 3 p38 and p42/44 MAPK signaling pathways regulate IL1-mediated OPG secretion in breast cancer cells. a Relative OPG mRNA and b OPG
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on the bottom of a 6-well plate before being incu-
bated with a Transwell insert containing breast can-
cer cells for 8 h (Fig. 5a). After this time point,
breast cancer cells were collected for OPG mRNA
analysis. In a parallel set up, the Transwell inserts
containing breast cancer cells were then moved to
fresh media for an additional 16 h, upon which the
supernatant was collected for OPG protein analysis.
The THP-1 macrophages indeed produced IL1B: 15.0
± 6.9 pg/mL (mean ± S.D., n = 3) of IL1B was detected
by ELISA from supernatant taken from THP-1 cells
cultured for 8 h. The co-cultures led to significantly
increased OPG mRNA and secreted protein in all
three breast cancer cells (Fig. 5b and c). To ascertain
the specificity of the IL1B-mediated effects, prior to
starting the co-culture IL-1RA (400 ng/mL) was
added to the media in one of the wells. Under these
conditions, the OPG mRNA levels (Fig. 5b), and es-
pecially the OPG secreted protein levels (Fig. 5c),
were indeed reduced.
Immunohistochemical staining of human primary
breast tumors for CD68, a pan-macrophage marker,
and OPG revealed that of the 46 samples tested 95.7
and 78.3%, respectively, exhibited moderate/strong
staining for these markers (Table 2, Fig. 5d and e).
Overall, 76.1% of these samples exhibited moderate/
strong crts a link between TAMs and OPG levels in
breast tumors.
OPG is important in the IL1B-enhanced invasion of breast
cancer cells
A number of studies in breast and prostate cancer, and
in melanoma show that tumor cells with increased inva-
siveness exhibit elevated and autocrine IL-1 production
Table 1 OPG mRNA expression is significantly correlated to
CCL2 and IL1B mRNA expression in breast cancer
Dataset CCL2 IL1B
R P R P
Bertucci - 266 0.269 8.8 • 10−6 0.177 3.8 • 10−3
Bos - 204 0.330 1.4 • 10−6 0.193 5.8 • 10−3
Chin-124 0.232 9.5 • 10−3 0.207 0.02
EXPO Breast - 351 0.153 4.2 • 10−3 0.200 1.6 • 10−4
Halfwerk - 947 0.077 0.02 n.s.
Iglehart-123 0.227 0.01 0.200 0.03
Miller-251 0.150 0.02 n.s.
Servant - 343 0.199 2.0 • 10−4 0.252 2.4 • 10−6
Smid - 210 0.312 4.0 • 10−6 0.198 4.0 • 10−3
TCGA Breast - 528 0.236 4.3 • 10−8 0.197 5.3 • 10−6
TCGA Breast - 1097 0.210 2.3 • 10−12 0.253 1.9 • 10−17
Wang - 286 0.212 3.1 • 10−4 0.165 5.1 • 10−3
Zhang - 136 0.293 5.3 • 10−4 0.295 5.0 • 10−4
13 of 13 11 of 13
OPG and CCL2/IL1B mRNA expression and correlation were analyzed in 13
human breast cancer datasets (See Materials and Methods). Columns from left
to right: Dataset name (and sample size), OPG-CCL2 correlation (r = correlation,
p = p value; significant and positive in all 13 datasets), and OPG-IL1B correl-
ation (significant and positive in 11 of 13 datasets). Correlations were calcu-
lated using a 2log Pearson test
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Fig. 4 CCL2, IL1B and OPG mRNA levels are elevated in human
breast cancer tissue samples. a CCL2, b IL1B and c OPG mRNA levels
were measured by qPCR on cDNA samples prepared from normal
and breast cancer human tissue samples. Data are represented as
delta Ct values after normalizing against β-actin (Ct value for genes
of interest minus Ct value of β-actin). Asterisks indicate statistical sig-
nificance (** p≤ 0.01, ****p ≤ 0.0001)
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Fig. 5 Co-culture with THP-1 macrophages induces OPG secretion in breast cancer cells. a Diagram of the transwell co-culture experiment set-up.
Breast cancer cells were co-cultured with THP-1 macrophages in the presence and absence of Interleukin-1 receptor antagonist (IL-1RA, 400 ng/mL).
b After 8 h of co-culture, relative OPG mRNA was measured by qRT-PCR, (n≥ 3). c Breast cancer cells were subsequently cultured alone in fresh media
for an additional 16 h and OPG secreted protein was measured from this supernatant by ELISA, (n≥ 3). OPG mRNA and secreted protein levels reveal
that the co-culture mediated induction of OPG expression in breast cancer cells were partially repressed by IL-1RA. d Representative image for d CD68
immunohistochemistry and e OPG immunohistochemistry on primary/malignant tumor sections on a human breast cancer tissue microarray. Images
are taken at 400× magnification. Data are represented by mean ± SD. Asterisks indicate statistical significance (p < 0.05)
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[10, 37]. IL1B has been shown to enhance the invasive-
ness of TNBC cells in vitro [38, 39] and in IL1B knock-
out mice, IL1B was essential for the invasiveness of B16
melanoma xenografts [11]. We have recently shown that
OPG can promote TNBC cell invasion, so OPG could be
a downstream mediator whereby IL1B promotes inva-
sion [24]. To investigate whether OPG indeed plays a
role in IL1B tumor-promoting effects, we assessed the
effects of OPG knockdown on IL1B-mediated cell inva-
sion. MDA-MB-436 cells were transfected with OPG tar-
geting or control siRNA. Twenty-four hours later, cells
were pre-treated with IL1B (10 ng/mL) or PBS in serum
reduced medium for 24 h. The invasion assay was car-
ried out for another 24 h. Although not statistically sig-
nificant, we consistently detected noticeably less
invasion of the OPG knockdown cells (Fig. 6a). We also
observed that the IL1B-induced cell invasion was signifi-
cantly elevated in control cells while repressed upon
OPG knockdown (Fig. 6a and b).
Matrix metalloproteinases (MMPs) influence cell pro-
liferation, apoptosis and angiogenesis, and play a key
role in promoting the invasiveness of tumor cells by
cleaving components of the extracellular matrix (ECM)
and basement membrane [40]. Han et al. reported that
MMP-1 and MMP-9 mRNA levels did not differ in
TNBC versus non-TNBC cells, but that MMP-3 mRNA
levels were higher in TNBC cells [39]. In this same study
the authors showed that MMP-3 mRNA and protein
were enhanced upon treatment with exogenous IL1B in
TNBC cells [39]. In mice, it has been shown that MMP3
over-expression in normal mammary epithelial cells led
to oncogenic transformation [41]. We therefore asked
whether OPG was important in IL1B-mediated MMP3
induction in breast cancer cells. MDA-MB-436 cells
were transfected with OPG targeting or control siRNA.
Cells were then treated with IL1B (10 ng/mL) or PBS in
serum reduced medium for 72 h prior to collection.
Consistent with the previous study, IL1B induced
MMP3 mRNA up-regulation in the control cells (Fig. 6d).
Upon OPG knockdown, IL1B-mediated MMP3 induc-
tion was repressed (Fig. 6c and d). It is known IL1B can
induce its own expression, acting in a positive-feedback
loop to enhance the IL-1 response [42]. Treatment with
exogenous IL1B elevated the IL1B mRNA levels in the
breast cancer cells (Fig. 6e). Interestingly, this IL1B-
mediated IL1B induction was also repressed upon OPG
knockdown (Fig. 6c and e).
Taken together, our findings suggest OPG is a down-
stream effector of IL1B-mediated invasion in breast can-
cer cells.
Discussion
Persistent inflammation is linked with cancer develop-
ment and progression [43]. It has been shown that treat-
ment with the inflammatory cytokine IL1B promotes the
invasiveness of breast cancer cells in vitro [38, 39]. In
our previous work we reported that the invasive and
metastatic capacity of TNBC cells was reduced upon
OPG knockdown [24]. In this study, we investigated
OPG in the context of its role in breast cancer and in-
flammation, with a particular focus on IL1B. Here we
provide mechanistic insight into the IL1B-OPG signaling
axis and reveal a potential role for OPG in the invasion-
promoting effects of IL1B. We show that OPG secretion
is induced by IL1B in a p38- and p42/44-dependent
manner, independent of breast cancer subtype or basal
OPG levels. Macrophages, but possibly also breast can-
cer cells themselves, may serve as local IL1B sources to
influence OPG secretion. Also, we show that IL1B-
mediated breast cancer cell invasion, and the induction
of MMP3 and IL1B itself, occurs in an OPG-dependent
manner.
Elevated OPG secretion has been detected in aggressive
tumors with poor patient outcome, including breast, lung,
prostate, gastric and bladder cancers [19, 20, 44–46]. In
breast cancer cells, OPG over-expression resulted in en-
hanced tumor growth [23] and increased pulmonary me-
tastasis in mice [47]. In agreement with these reports, we
have shown that TNBC cells, representing the most ag-
gressive breast cancer subtype, secreted higher basal OPG
levels than non-TNBC cells. Similarly, we showed that
TNBC cells secreted higher IL1B levels than non-TNBC
cells, which exhibited little to no IL1B secretion. These re-
sults are consistent with a study indicating that the non-
TNBC cell line HCC1954 produces low IL1B amounts
[48]. We found that regardless of the basal OPG and IL1B
levels, all breast cancer cell lines remained responsive to
IL1B-mediated OPG induction, with the highest induction
of OPG secretion in the non-TNBC cells (Fig. 1c and d).
Taking into account the association of higher OPG and
IL1B basal levels in TNBC cells, we treated the TNBC
type MDA-MB-436 cell line with the IL1B receptor antag-
onist IL-1RA. This resulted in the partial repression of
basal OPG secretion suggesting an autocrine loop, by
which IL1B produced by cells is linked to the higher basal
expression of OPG.
Table 2 CD68 and OPG are commonly co-expressed in primary
breast tumors
% with moderate/
strong CD68 staining
% with moderate/
strong OPG staining
Co-occurrence of moderate/
strong CD68 and OPG staining
95.7 78.3 35 out of 46 tumors = 76.1%
CD68 and OPG protein levels were assessed by immunohistochemistry in
tissue microarray slides containing human patient primary breast cancer
samples (see Methods). Two left columns: data is shown as the percentage of
samples presenting with moderate/strong CD68 and OPG staining. Right
column: co-occurrence of CD68 and OPG staining represent the detection of
moderate/strong expression of both CD68 and OPG within the same
patient sample
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Fig. 6 IL1B promotes the invasion of breast cancer cells in an OPG-dependent manner. MDA-MB-436 breast cancer cells transfected with OPG
(siOPG1) or negative control (siNeg) siRNA were pretreated with IL1B (10 ng/mL), and subsequently assayed for invasiveness. a IL1B-mediated cell
invasion is reduced in OPG knockdown cells, (n = 3). Data is represented as relative fluorescence units (RFU) fold change relative to the untreated
negative control. b OPG knockdown in the breast cancer cells used in the cell invasion assay was assessed at the end point of the experiment.
Knockdown was verified by qRT-PCR. MDA-MB-436 cells transfected with OPG or control siRNA were treated with IL1B or PBS (10 ng/mL) for 72 h.
c OPG knockdown at 72 h was verified by qRT-PCR. Assessment of d MMP3 and e IL1B mRNA levels indicate the IL1B-mediated induction is inhib-
ited by OPG depletion, (n = 3). Data are represented by mean ± SD. Asterisks indicate statistical significance (p < 0.05). f Signaling model. IL1B se-
creted from macrophages and/or from breast cancer cells themselves, activate p38 and p42/44 MAPK signaling in the breast cancer cells resulting in
increased OPG secretion. In turn, this OPG secretion up-regulation promotes the invasiveness of breast cancer cells. OPG levels in breast tumors
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The mitogen-activated protein kinase (MAPK) signaling
pathway is often activated in cancer [49, 50]. Indeed, p38
and p42/44 MAPK signaling have been associated with
breast cancer invasion and progression. In breast cancer
cells it has been reported that elevated p38 MAPK signal-
ing can drive invasiveness and chemoresistance of HER2-
overexpressing cells [35]. Another study has reported that
patients with lymph node-positive breast carcinoma
showed shorter progression-free survival when their pri-
mary tumors expressed high levels of phosphorylated p38
[32]. In a study examining primary human breast tumors,
11 out of 23 samples showed active p42/44, significantly
elevated relative to adjacent matched normal breast tissue
[51]. Interestingly, it has been reported that TNBC, basal-
like type breast cancer cell lines, relative to breast cancer
cell lines representative of the other subtypes, exhibit a
greater sensitivity to p42/44 MEK1/2 inhibitors [52, 53].
In our inhibitor studies we confirmed that both p38 and
p42/44 MAPK activities mediated IL1B-induced OPG se-
cretion. This effect was observed independent of breast
cancer subtype. Therefore our results show that IL1B-
induced OPG secretion is regulated by the p38 and p42/
44 MAPK pathways in breast cancer cells.
In an analysis of publicly available human breast can-
cer genome-wide mRNA expression datasets from pa-
tient samples we showed that OPG mRNA expression
was significantly correlated with IL1B mRNA expression.
This correlation is consistent with in vitro experiments
showing that IL1B and OPG levels were either both ele-
vated or both relatively lower in TNBC cells and non-
TNBC cells, respectively. CCL2 mRNA expression was
also found to be significantly correlated with OPG
mRNA expression. CCL2 is a potent chemo-attractant
involved in macrophage tissue infiltration. TAMs are
present in many solid tumors, including breast cancer.
Clinical studies have indicated TAM levels are correlated
with breast cancer prognosis [54], and experimental evi-
dence showed that CCL2 levels are significantly associ-
ated with TAM numbers [36, 55] and TAM retention
[56], implicating CCL2 in breast cancer progression.
Furthermore, we showed relative to normal breast tissue
that elevated levels of CCL2, IL1B and OPG mRNA
levels were detected in stage I breast cancer human tis-
sue samples. We asked whether macrophages could
serve as an IL1B source to influence OPG expression in
breast cancer cells. Upon co-culture with THP-1 macro-
phages, OPG was significantly induced in breast cancer
cells. This induction was partially repressed in the pres-
ence of IL-1RA, indicating that the effects on OPG were
specific to IL1B. The potential causative link between
macrophages and elevated OPG levels were further sup-
ported by the immunohistochemical analyses of pan-
macrophage marker CD68 and OPG which indicated a
co-occurrence of these two markers in human primary
breast tumors. Studies have shown that IL1B and the p38
and p42/44 MAPK pathways play important roles in tumor
cell progression [9, 31, 34, 35, 38, 39, 51–53, 57–59]. Given
our data demonstrating that OPG is subject to regulation
by IL1B-p38 and -p42/44 signaling, we sought to investi-
gate OPG function in IL1B-mediated breast cancer inva-
sion. Our results showed that IL1B treatment significantly
elevated the invasiveness of MDA-MB-436 cells. Interest-
ingly, these effects were inhibited upon OPG knockdown.
MMPs play key roles in promoting the invasive properties
of tumor cells [40]. Particularly, MMP3 has been shown to
drive the formation of mammary tumors in mice when
over-expressed in mammary epithelial cells [41]. Addition-
ally, MMP3 mRNA levels had been reported to be elevated
in TNBC cells versus non-TNBC cells, where treatment
with exogenous IL1B could lead to MMP3 up-regulation
[39]. In line with this published study, treatment of MDA-
MB-436 with IL1B cells induced MMP3 expression. We
show IL1B treatment can lead to IL1B up-regulation
(Fig. 4d). Induction of both MMP3 and IL1B were re-
pressed in cells treated with OPG siRNA (Figs. 4c-e), this is
in agreement with our previous study showing reduced
invasion upon OPG knockdown in TNBC cell lines
[24]. The effects of OPG knockdown on IL1B induction
suggest that IL1B expression may also be subject to
regulation by OPG. Further studies are needed to de-
fine this cross-regulation between OPG and IL1B. In
any case, the interdependent effects of OPG and IL1B
expressions further support the significance of OPG in
inflammatory-driven tumor progression.
Conclusions
In summary, we have identified OPG as a potential
downstream effector in the metastasis-promoting effects
of IL1B in breast cancer. IL1B from macrophages or
from breast cancer cells themselves can induce OPG se-
cretion in a p38- and p42/44-dependent manner that
contributes to increased invasion (Fig. 6f ). The increased
invasion promoted by IL1B and OPG involves MMP3
induction as well as an IL1B auto-amplification loop.
This study presents a novel pathway whereby inflamma-
tion could promote breast cancer progression.
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